|
| 產(chǎn)地 | 進(jìn)口、國(guó)產(chǎn) |
| 品牌 | 上海莼試 |
| 保存條件 | Store at -20 °C |
| 貨號(hào) | CS10631 |
| 應(yīng)用范圍 | WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500 |
| CAS編號(hào) | |
| 抗體名 | Anti-FAK/PTK2 |
| 克隆性 | |
| 靶點(diǎn) | 詳見(jiàn)說(shuō)明書(shū) |
| 適應(yīng)物種 | 詳見(jiàn)說(shuō)明書(shū) |
| 形態(tài) | 詳見(jiàn)說(shuō)明書(shū) |
| 宿主 | 詳見(jiàn)說(shuō)明書(shū) |
| 亞型 | IgG |
| 標(biāo)識(shí)物 | 詳見(jiàn)說(shuō)明書(shū) |
| 濃度 | 1mg/1ml% |
| 免疫原 | KLH conjugated synthetic peptide derived from human FAK C-terminus |
產(chǎn)品訂購(gòu)信息：
英文名稱 Anti-FAK/PTK2
中文名稱 粘著斑激酶抗體品牌
別 名 FADK 1; FADK; FAK 1; FAK related non kinase polypeptide; FAK1; Focal adhesion kinase 1; FRNK; pp125FAK; Protein tyrosine kinase 2; Protein Tyrosine Kinase Cytoplasmic; PTK 2; FAK1_HUMAN; Focal adhesion kinase-related nonkinase; Protein phosphatase 1 regulatory subunit 71; PPP1R71; Protein-tyrosine kinase 2; p125FAK.
濃 度 1mg/1ml
規(guī) 格 0.1ml/100μg 0.2ml/200μg
抗體來(lái)源 Rabbit
克隆類型 polyclonal
交叉反應(yīng) Human, Mouse, Rat
產(chǎn)品類型 一抗
研究領(lǐng)域 細(xì)胞生物 免疫學(xué) 激酶和磷酸酶
蛋白分子量 predicted molecular weight: 116kDa
性 狀 Lyophilized or Liquid
免 疫 原 KLH conjugated synthetic peptide derived from human FAK C-terminus
亞 型 IgG
純化方法 affinity purified by Protein A
儲(chǔ) 存 液 0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide
粘著斑激酶抗體品牌 產(chǎn)品應(yīng)用 WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
（石蠟切片需做抗原修復(fù)）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
保存條件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
Important Note This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
產(chǎn)品介紹 Non-receptor protein-tyrosine kinase implicated in signaling pathways involved in cell motility, proliferation and apoptosis. Activated by tyrosine-phosphorylation in response to either integrin clustering induced by cell adhesion or antibody cross-linking, or via G-protein coupled receptor (GPCR) occupancy by ligands such as bombesin or lysophosphatidic acid, or via LDL receptor occupancy. Plays a potential role in oncogenic transformations resulting in increased kinase activity. [SUBCELLULAR LOCATION] Cell junction, focal adhesion. Cell membrane; Peripheral membrane protein; Cytoplasmic side. Note=Constituent of focal adhesions.
Function : Non-receptor protein-tyrosine kinase that plays an essential role in regulating cell migration, adhesion, spreading, reorganization of the actin cytoskeleton, formation and disassembly of focal adhesions and cell protrusions, cell cycle progression, cell proliferation and apoptosis. Required for early embryonic development and placenta development. Required for embryonic angiogenesis, normal cardiomyocyte migration and proliferation, and normal heart development. Regulates axon growth and neuronal cell migration, axon branching and synapse formation; required for normal development of the nervous system. Plays a role in osteogenesis and differentiation of osteoblasts. Functions in integrin signal transduction, but also in signaling downstream of numerous growth factor receptors, G-protein coupled receptors (GPCR), EPHA2, netrin receptors and LDL receptors. Forms multisubunit signaling complexes with SRC and SRC family members upon activation; this leads to the phosphorylation of additional tyrosine residues, creating binding sites for scaffold proteins, effectors and substrates. Regulates numerous signaling pathways. Promotes activation of phosphatidylinositol 3-kinase and the AKT1 signaling cascade. Promotes activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling cascade. Promotes localized and transient activation of guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs), and thereby modulates the activity of Rho family GTPases. Signaling via CAS family members mediates activation of RAC1. Recruits the ubiquitin ligase MDM2 to P53/TP53 in the nucleus, and thereby regulates P53/TP53 activity, P53/TP53 ubiquitination and proteasomal degradation. Phosphorylates SRC; this increases SRC kinase activity. Phosphorylates ACTN1, ARHGEF7, GRB7, RET and WASL. Promotes phosphorylation of PXN and STAT1; most likely PXN and STAT1 are phosphorylated by a SRC family kinase that is recruited to autophosphorylated PTK2/FAK1, rather than by PTK2/FAK1 itself. Promotes phosphorylation of BCAR1; GIT2 and SHC1; this requires both SRC and PTK2/FAK1. Promotes phosphorylation of BMX and PIK3R1. Isoform 6 (FRNK) does not contain a kinase domain and inhibits PTK2/FAK1 phosphorylation and signaling. Its enhanced expression can attenuate the nuclear accumulation of LPXN and limit its ability to enhance serum response factor (SRF)-dependent gene transcription.
Subunit : Interacts (via first Pro-rich region) with CAS family members (via SH3 domain), including BCAR1, BCAR3, CASS4 and NEDD9. Interacts with GIT1. Interacts with SORBS1. Interacts with RGNEF. Interacts with SHB. Interacts with PXN and TLN1. Interacts with STAT1. Interacts with DCC. Interacts with WASL. Interacts with ARHGEF7. Interacts with GRB2 and GRB7 (By similarity). Component of a complex that contains at least FER, CTTN and PTK2/FAK1. Interacts with BMX. Interacts with TGFB1I1. Interacts with STEAP4. Interacts with ZFYVE21. Interacts with ESR1. Interacts with PIK3R1 or PIK3R2. Interacts with SRC, FGR, FLT4 and RET. Interacts with EPHA2 in resting cells; activation of EPHA2 recruits PTPN11, leading to dephosphorylation of PTK2/FAK1 and dissociation of the complex. Interacts with EPHA1 (kinase activity-dependent). Interacts with CD4; this interaction requires the presence of HIV-1 gp120. Interacts with PIAS1. Interacts with ARHGAP26 and SHC1. Interacts with RB1CC1; this inhibits PTK2/FAK1 activity and activation of downstream signaling pathways. Interacts with P53/TP53 and MDM2. Interacts with LPXN (via LD motif 3).
Subcellular Location : Cell junction, focal adhesion. Cell membrane; Peripheral membrane protein; Cytoplasmic side. Cytoplasm, cell cortex. Cytoplasm, cytoskeleton. Cytoplasm, cytoskeleton, centrosome. Nucleus. Note=Constituent of focal adhesions. Detected at microtubules.
Post-translational modifications : Phosphorylated on tyrosine residues upon activation, e.g. upon integrin signaling. Tyr-397 is the major autophosphorylation site, but other kinases can also phosphorylate this residue. Phosphorylation at Tyr-397 promotes interaction with SRC and SRC family members, leading to phosphorylation at Tyr-576, Tyr-577 and at additional tyrosine residues. FGR promotes phosphorylation at Tyr-397 and Tyr-576. FER promotes phosphorylation at Tyr-577, Tyr-861 and Tyr-925, even when cells are not adherent. Tyr-397, Tyr-576 and Ser-722 are phosphorylated only when cells are adherent. Phosphorylation at Tyr-397 is important for interaction with BMX, PIK3R1 and SHC1. Phosphorylation at Tyr-925 is important for interaction with GRB2. Dephosphorylated by PTPN11; PTPN11 is recruited to PTK2 via EPHA2 (tyrosine phosphorylated). Microtubule-induced dephosphorylation at Tyr-397 is crucial for the induction of focal adhesion disassembly; this dephosphorylation could be catalyzed by PTPN11 and regulated by ZFYVE21.
Sumoylated; this enhances autophosphorylation.
DISEASE : Note=Aberrant PTK2/FAK1 expression may play a role in cancer cell proliferation, migration and invasion, in tumor formation and metastasis. PTK2/FAK1 overexpression is seen in many types of cancer.
Similarity : Belongs to the protein kinase superfamily. Tyr protein kinase family.
FAK subfamily.
Contains 1 FERM domain.
Database links : UniProtKB/Swiss-Prot: Q05397.2
FAK是整合蛋白介導(dǎo)的信號(hào)轉(zhuǎn)導(dǎo)中的重要成員,有酪氨酸蛋白激酶活性,并可自身磷酸化,FAK本身是胱冬肽酶(caspase)的底物。作為信號(hào)分子的FAK參與的調(diào)節(jié)。
1.FAK 局部粘著斑激酶，是一種酪氨酸激酶;細(xì)胞的侵襲性生長(zhǎng)是一個(gè)多步驟的復(fù)雜過(guò)程，有多種生物化學(xué)因子參與其中,局部粘著斑激酶（focal adhesion kinase, FAK）介導(dǎo)的信號(hào)轉(zhuǎn)導(dǎo)系統(tǒng)就是其中最為重要的細(xì)胞信號(hào)轉(zhuǎn)導(dǎo)途徑之一。細(xì)胞必須黏附于細(xì)胞外基質(zhì)，通過(guò)促進(jìn)依賴于PTK激酶活性的細(xì)胞外基質(zhì)信號(hào)轉(zhuǎn)導(dǎo)，進(jìn)而影響細(xì)胞的黏附、運(yùn)動(dòng)與遷移。
2.粘著斑激酶(focal adhesion kinase,FAK)是整合蛋白介導(dǎo)的信號(hào)轉(zhuǎn)導(dǎo)中的重要成員,有酪氨酸蛋白激酶活性,并可自身磷酸化；為信號(hào)分子的FAK,還與細(xì)胞內(nèi)其他信號(hào)轉(zhuǎn)導(dǎo)通路存在串話(crosstalk),直接參與了細(xì)胞多種功能的調(diào)節(jié)。
3.盡管FAK的確切功能尚不清楚,但若干實(shí)驗(yàn)均提示FAK可能有兩個(gè)作用,一是在細(xì)胞鋪展和移動(dòng)時(shí),FAK參與粘著斑形成和調(diào)節(jié)；二是FAK參與信號(hào)轉(zhuǎn)導(dǎo)過(guò)程,以告知細(xì)胞核其細(xì)胞已錨定了。近年有關(guān)FAK在細(xì)胞凋亡中的作用也業(yè)已肯定。
Anti-Gastrin/FITC 熒光素標(biāo)記胃泌素/蛙皮素抗體IgGMulti-class antibodies規(guī)格： 0.2ml
Anti-Phospho-NMDAR1 (Ser896) /FITC 熒光素標(biāo)記磷酸化谷氨酸受體1抗體IgGMulti-class antibodies規(guī)格： 0.2ml
Rhesus antibody Rh Bone Sialoprotein/BSP 骨涎蛋白 規(guī)格 0.1ml
HSP-60( Heat shock protein-60) 熱休克蛋白-60(抗原) 0.5mg
HSPABP/HIP/HSC70 Interacting Protein HIP 英文名稱： 熱休克蛋白70相互作用蛋白抗體 0.2ml
Rhesus antibody Rh Reprimo 細(xì)胞質(zhì)內(nèi)的糖基化蛋白抗體 規(guī)格 0.1ml
Anti-Phospho-NMDAR1 (Ser896) /FITC 熒光素標(biāo)記磷酸化谷氨酸受體1抗體IgGMulti-class antibodies規(guī)格： 0.2ml
GHRP-Ghrelin(Human growth hormone releasing peptide-Ghrelin) ELISA Kit 人生長(zhǎng)激素釋放肽ghrelinMulti-class antibodies規(guī)格： 96T
Anti-Phospho-Stathmin (Ser16) 磷酸化原癌基因蛋白18Multi-class antibodies規(guī)格： 0.1ml
Rhesus antibody Rh LAG-3/CD223 淋巴細(xì)胞活化基因-3抗體 規(guī)格 0.2ml
U S-GH(Human Ultra Sensitive growth hormone) ELISA Kit 人超敏生長(zhǎng)激素 96T
PPP2R1B 英文名稱： 蛋白質(zhì)磷酸酶2調(diào)節(jié)亞基1B抗體 0.2ml
CHCHD1 英文名稱： 卷曲螺旋結(jié)構(gòu)域蛋白CHCHD1抗體 0.1ml
Anti-Phospho-Stathmin (Ser16) 磷酸化原癌基因蛋白18Multi-class antibodies規(guī)格： 0.1ml
AChE(Human Acetylcholinesterase) ELISA Kit 人乙酰膽堿酯酶Multi-class antibodies規(guī)格： 48T
Anti-NFBD1/MDC1 DNA損傷關(guān)卡蛋白1抗體Multi-class antibodies規(guī)格： 0.2ml
Rhesus antibody Rh IL-1RA 白介素-1受體拮抗劑抗體 規(guī)格 0.2ml
LIF ELISA Kit 大鼠抑制因子 96T
Phospho-Paxillin(Tyr88) 英文名稱： 磷酸化樁蛋白Paxillin抗體 0.1ml
COX IV 英文名稱： 細(xì)胞色素c氧化酶IV亞型1抗體 0.2ml
Anti-NFBD1/MDC1 DNA損傷關(guān)卡蛋白1抗體Multi-class antibodies規(guī)格： 0.2ml
CL-0261BC-022(人癌細(xì)胞)5×106cells/瓶×2
IFNB1 Others Mouse 小鼠 IFNB1 / IFN-beta / Ierferon beta 人細(xì)胞裂解液 (陽(yáng)性對(duì)照)
人髓核細(xì)胞cDNAHNPC cDNA
T47D細(xì)胞，人管癌細(xì)胞 豬腎細(xì)胞系,IBRS-2細(xì)胞 Many types of cells包裝：5 × 105次方(1ml)
MC3T3-E1(小鼠胚胎成骨細(xì)胞前體細(xì)胞) 5×106cells/瓶×2
HCMEC Pellet 人微內(nèi)皮細(xì)胞團(tuán)塊 > 1 mio.cells 纖維母細(xì)胞粘附檢測(cè)試劑盒Fibro
CL-0259BC-020(人癌細(xì)胞)5×106cells/瓶×2
FAM171B Others Human 人 FAM171B / KIAA1946 人細(xì)胞裂解液 (陽(yáng)性對(duì)照)
人顱骨造骨細(xì)胞cDNAHCO cDNA
豬腎細(xì)胞;PK(15) 細(xì)胞，F(xiàn)O細(xì)胞 G422細(xì)胞，KM小鼠腦神經(jīng)膠質(zhì)母細(xì)胞瘤瘤株
表達(dá)SV40T和EBNA1的人胚腎細(xì)胞;293ET
HA Others H5N1 甲型 H5N1 (A/Egypt/2321-NAMRU3/2007) 血凝素 (Hemagglutinin / HA) 人細(xì)胞裂解液 (陽(yáng)性對(duì)照)
粘著斑激酶抗體品牌 IL12A & IL12B Others Mouse 小鼠 IL12A & IL12B Heterodimer 人細(xì)胞裂解液 (陽(yáng)性對(duì)照)
兔主動(dòng)脈平滑肌細(xì)胞;SMC
J82 人膀胱移行細(xì)胞癌
NCI-H716 [H716]人結(jié)直腸腺癌細(xì)胞 NCI-H716 [H716] human colorectal adenocarcinoma cells RPMI-1640(GIBCO)+10%FBS
VEGFA Protein Human 重組人 / 食蟹猴 VEGF / VEGFA / VEGF165 蛋白
小鼠中腦縫神經(jīng)細(xì)胞(腦脊)(MN-r)(1×106) HT-29, 人細(xì)胞 Human
抗體的生物素化標(biāo)記實(shí)驗(yàn)要點(diǎn)：
1. 粘著斑激酶抗體品牌 如在反應(yīng)混合液中有疊氮鈉或游離氨基存在,會(huì)抑制標(biāo)記反應(yīng)。因此,蛋白質(zhì)在反應(yīng)前要對(duì) 0.1mol/L碳酸氫鈉緩沖液或0.5mol/L硼酸緩沖液充分透析；
2.所用的NHSB及待生物素化蛋白質(zhì)之間的分子比按蛋白質(zhì)表面的ε-氨基的密度會(huì)有所不同,選擇不當(dāng)則影響標(biāo)記的效率,應(yīng)先用幾個(gè)不同的分子比來(lái)篩選最適條件；
3.用NHSB量過(guò)量也是不利的,抗原的結(jié)合位點(diǎn)可能因此被封閉,導(dǎo)致抗體失活；
4.由于抗體的氨基不易接近可能造成生物素化不足,此時(shí)可加入去污劑如 Triton x-100, Tween20等；
5.當(dāng)游離ε-氨基(賴氨酸殘基的氨基)存在于抗體的抗原結(jié)合位點(diǎn)時(shí),或位于酶的催化位點(diǎn)時(shí),生物素化會(huì)降低或損傷抗體蛋白的結(jié)合力或活性；
6.生物素還可能與不同的功能基團(tuán),如羰基、氨基、巰基、異咪唑基及*基,也可與糖基共價(jià)結(jié)合；
7.交聯(lián)反應(yīng)后,應(yīng)充分透析,否則,殘余的生物素會(huì)對(duì)生物素化抗體與親和素的結(jié)合產(chǎn)生競(jìng)爭(zhēng)作用；
8.在細(xì)胞的熒光標(biāo)記實(shí)驗(yàn)中,中和親和素的本底低,但由于鏈霉親和素含有少量正電荷,故對(duì)某些細(xì)胞可導(dǎo)致高本底。
抗體的鑒定：
1）粘著斑激酶抗體品牌 抗體的效價(jià)鑒定：不管是用于診斷還是用于,制備抗體的目的都是要求較高效價(jià)。不同的抗原制備的抗體,要求的效價(jià)不一。鑒定效價(jià)的方法很多,包括有試管凝集反應(yīng),瓊脂擴(kuò)散試驗(yàn),酶聯(lián)免疫吸附試驗(yàn)等。常用的抗原所制備的抗體一般都有約成的鑒定效價(jià)的方法,以資比較。如制備抗抗體的效價(jià),一般就采用瓊脂擴(kuò)散試驗(yàn)來(lái)鑒定。
2）抗體的特異性鑒定：抗體的特異性是指與相應(yīng)抗原或近似抗原物質(zhì)的識(shí)別能力?？贵w的特異性高,它的識(shí)別能力就強(qiáng)。衡量特異性通常以交叉反應(yīng)率來(lái)表示。交叉反應(yīng)率可用競(jìng)爭(zhēng)抑制試驗(yàn)測(cè)定。以不同濃度抗原和近似抗原分別做競(jìng)爭(zhēng)抑制曲線,計(jì)算各自的結(jié)合率,求出各自在IC50時(shí)的濃度,并按公式計(jì)算交叉反應(yīng)率。
如果所用抗原濃度IC50濃度為pg/管,而一些近似抗原物質(zhì)的IC50濃度幾乎是無(wú)窮大時(shí),表示這一抗血清與其他抗原物質(zhì)的交叉反應(yīng)率近似為0,即該血清的特異性較好。
3）抗體親和力：是指抗體和抗原結(jié)合的牢固程度。親和力的高低是由抗原分子的大小,抗體分子的結(jié)合位點(diǎn)與抗原決定簇之間立體構(gòu)型的合適度決定的。有助于維持抗原抗體復(fù)合物穩(wěn)定的分子間力有氫鍵,疏水鍵,側(cè)鏈相反電荷基因的庫(kù)侖力,范德華力和空間斥力。親和力常以親和常數(shù)K表示,K的單位是L/mol?？贵w親和力的測(cè)定對(duì)抗體的篩選,確定抗體的用途,驗(yàn)證抗體的均一性等均有重要意義。
|
|
|
|
|
